Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 15, 2021

Primary Completion Date

February 24, 2022

Study Completion Date

February 24, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

TNM002

TNM002, intramuscular injection

DRUG

Placebo

Placebo, intramuscular injection

Trial Locations (1)

The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai

All Listed Sponsors

lead

Zhuhai Trinomab Pharmaceutical Co., Ltd.

INDUSTRY

NCT05842798 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults | Biotech Hunter | Biotech Hunter